PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 2 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 2 months ago Theralase Technologies conclut un placement privé de 666 400 $CAN Placement Privé Cancer De La Vessie Technologies Théralase Mandats Stade Clinique
BRIEF published on 11/15/2024 at 13:05, 1 year 2 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 2 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 3 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
BRIEF published on 11/13/2024 at 00:28, 1 year 3 months ago Theralase Technologies prolonge l'expiration du mandat jusqu'en 2027 Bourse De Croissance TSX Traitement Du Cancer Technologies Théralase Développement Pharmaceutique Prolongation Du Mandat
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 3 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 4 months ago Mises à jour de Theralase sur l'étude clinique sur le cancer de la vessie Approbation De La FDA Étude Clinique Theralase Cancer De La Vessie Ruvidar
BRIEF published on 10/07/2024 at 13:05, 1 year 4 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 4 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 02/13/2026 at 17:45, 3 hours 51 minutes ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 7 hours 1 minute ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/13/2026 at 14:30, 7 hours 6 minutes ago Golden Harp Resources Inc. Receives TSXV Final Acceptance and Closes Acquisition to Create District-Scale Copper Hill Land Package
Published on 02/13/2026 at 14:00, 7 hours 36 minutes ago Troubadour Resources Reports Assay Results from Drill Program at Senneville Gold-Silver-Copper Property
Published on 02/13/2026 at 13:37, 7 hours 59 minutes ago Atlas Salt Expands Strategic MOU with Sandvik Mining Supporting $132 Million of Equipment and Services at Great Atlantic Salt Project
Published on 02/13/2026 at 19:20, 2 hours 16 minutes ago Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 2 hours 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 3 hours 16 minutes ago GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:07, 3 hours 29 minutes ago EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range
Published on 02/13/2026 at 17:58, 3 hours 38 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/13/2026 at 18:05, 3 hours 31 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 3 hours 31 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 3 hours 46 minutes ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 3 hours 46 minutes ago Nombre total d'actions et droits de vote - janvier 2026
Published on 02/13/2026 at 17:34, 4 hours 2 minutes ago Déclaration des transactions sur actions propres réalisées du 02/02/2026 au 06/02/2026
